永昕生物醫藥股份有限公司 Approved
最後更新時間 2025/05/18 , 02:43 AM
最後更新時間 2025/05/18 , 02:43 AM
負責人
Chen,Pei-Jun
統一編號
12905993
成立日期
2001/09/28
資本額
NT$5,000,000,000
實收資本額
NT$2,070,069,000
股票代號
4726
電話
036-670880
地址
7F, No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County, 302, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Chen,Pei-Jun Chairman 20.28% Center Laboratories, Inc.
Chen,Jun-Hong Director 20.28% Center Laboratories, Inc.
Jason Technology Co., Ltd. Director 0.63%
ZHONG JIA INVESTMENT DEVELOPMENT CO., LTD. Director 0.11%
Gao,Guo-Bin Independent Director 0.00%
Cai,Yu-Sheng Independent Director 0.00%
Zhao,Yu-Tian Independent Director 0.00%
Yan,Guo-Long Independent Director 0.00%
營業項目
  • Manufacture of Drugs and Medicines(200211)
  • Manufacture of Drugs and Medicines(200212)
  • Wholesale of Pharmaceutical and Medical Goods(457112)
  • Manufacture of Medicinal Biological Products(200300)
  • 公司歷程
  • Change Person in Charge to Chen,Pei-Jun
    2022/10/26
  • Change Capital to 5,000,000,000
    2020/07/01
  • Change Capital to 2,500,000,000
    2019/07/05
  • Change Person in Charge to Lin,Rong-Jin
    2018/12/21
  • Change Person in Charge to Chen,De-Li
    2015/11/09
  • Change Capital to 1,500,000,000
    2013/03/05
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 121,716 683,924 652,620
    Operating cost 200,213 925,281 1,027,811
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) -78,497 -241,357 -375,191
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net -78,497 -241,357 -375,191
    Operating expenses 49,708 220,180 226,911
    Other gain (loss), net - - -
    Operating profit (loss) -128,205 -461,537 -602,102
    Non-operating income and expenses -1,957 -8,049 -81,879
    Net profit (loss) before tax -130,162 -469,586 -683,981
    Income tax expense (benefits) -1,025 -2,461 -1,134
    Net profit (loss) of ongoing business for the current period -129,137 -467,125 -682,847
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -129,137 -467,125 -682,847
    Other comprehensive profit (loss), net 59 485 175
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -129,078 -466,640 -682,672
    Net profit (loss) attributable to owners of parent company -129,137 -467,125 -682,847
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -129,078 -466,640 -682,672
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -2 -3
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities 14,288 -191,681 -131,178
    Net cash inflows (outflows) from investing activities -108,614 -174,931 -443,148
    Net cash inflow (outflow) from financing activities 90,113 116,575 -229,732
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 74 334 -39
    Increase (decrease) in cash and cash equivalents in the current period -4,139 -249,703 -804,097
    Beginning balance of cash and cash equivalents 269,565 519,268 1,323,365
    Ending balance of cash and cash equivalents 265,426 269,565 519,268
    項目 2025 2024 2023
    Current asset 713,574 736,381 1,098,010
    Non-current asset 2,625,835 2,631,995 2,672,391
    Total asset 3,339,409 3,368,376 3,770,401
    Current liability 779,625 661,496 753,423
    Non-current liability 662,265 683,401 569,786
    Total liability 1,441,890 1,344,897 1,323,209
    share capital 2,071,191 2,070,508 2,057,884
    Equity - secruity token - - -
    capital reserve 423,334 421,109 1,074,289
    retained earning -596,044 -466,907 -682,641
    Other equity -962 -1,231 -2,340
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,897,519 2,023,479 2,447,192
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 1,897,519 2,023,479 2,447,192
    Share capital awaiting retirement (unit: share) 0 0 200,000
    Issued shares of advance equity (unit: shares) 3,000 14,900 36,000
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 9 9 11
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    存款不足之退票事宜
    時間 金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-04 0~0.5M 1~2M
    2023 01-12 7~8M 1~2M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • MYCENAX設計字(彩色)
  • tpgbiologics
  • tpgbiologics
  • Mycenax
  • 瑪力優
  • GranNEX
  • TuNEX
  • Mycenax永昕生物醫藥
  • 專利
  • 一種使用於生物反應器的可棄式過濾裝置
  • 政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Return security deposit
    2020
  • Confirmation of the existence of debt
    2018
  • Confirmation of employment relationship, etc.
    2024
  • Others
    2009
  • Return stock
    2004, 2006, 2007, 2008, 2009
  • Invalidating Judgment
    2008
  • Promissory note ruling
    2017
  • Confirmation of the existence of debt
    2020
  • Confirmation of the non-existence of the debt
    2019, 2020
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    2022/07/05 Article 24 of the Occupational Safety and Health Act
    2019/01/08 Paragraph 2, Article 21 of the Gender Equlity in Employment Act
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。